Fig 1: Receiver operating characteristic (ROC) curve assay of the selected exosomal proteins as diagnostic biomarkers. (A) ROC-AUC of GSN was 0.8309 (0.7343 to 0.9274, P<0.0001). (B) ROC-AUC of FGA was 0.8459 (0.7602 to 0.9317, P<0.0001). (C) ROC-AUC of FGG was 0.7447 (0.6323 to 0.8571, P<0.0001). (D) ROC-AUC of LBP was 0.6588 (0.5381 to 0.7794, P<0.001). GSN, gelsolin; FGA, fibrinogen alpha chain; LBP, lipopolysaccharide binding protein; FGG, fibrinogen gamma chain.
Fig 2: Prognostic significance of FGG and LBP estimated by simulated Kaplan-Meier analysis. Both overall survival (OS) and progression-free survival (PFS) were evaluated. The hazard ratio (HR) was utilized to describe the efficiency of prognostic markers and log-rank test was performed to demonstrate their statistical significance (34). (A) Estimated OS of FGG in ovarian cancer. (B) Estimated PFS of FGG in ovarian cancer. (C) Estimated OS of LBP in ovarian cancer. (D) Estimated PFS of LBP in ovarian cancer. FGG, fibrinogen gamma chain; LBP, lipopolysaccharide binding protein.
Fig 3: ELISA data of exosomal GSN, FGA, LBP and FGG expression. (A) Exosomal GSN expression in cancer and non-cancerous patients (****P<0.0001). (B) Exosomal FGA expression in cancer and non-cancerous patients (****P<0.0001). (C) Exosomal LBP expression in cancer and non-cancerous patients (**P<0.01). (D) Exosomal FGG expression in cancer and non-cancerous patients (****P<0.0001). GSN, gelsolin; FGA, fibrinogen alpha chain; LBP, lipopolysac-charide binding protein; FGG, fibrinogen gamma chain.
Supplier Page from Wuhan Fine Biotech Co., Ltd. for Human FGG(Fibrinogen gamma chain) ELISA Kit